NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 92 filers reported holding NUVALENT INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,359,463 | +9.9% | 247,106 | +0.8% | 0.00% | 0.0% |
| Q2 2023 | $10,338,143 | +123.8% | 245,154 | +38.4% | 0.00% | +100.0% |
| Q1 2023 | $4,620,330 | -13.0% | 177,092 | -0.7% | 0.00% | 0.0% |
| Q4 2022 | $5,309,595 | +95.4% | 178,294 | +27.6% | 0.00% | 0.0% |
| Q3 2022 | $2,717,000 | +57.1% | 139,778 | +9.6% | 0.00% | – |
| Q2 2022 | $1,730,000 | -10.8% | 127,586 | -8.6% | 0.00% | – |
| Q1 2022 | $1,939,000 | +3.4% | 139,571 | +41.7% | 0.00% | – |
| Q4 2021 | $1,875,000 | -11.3% | 98,497 | +5.0% | 0.00% | – |
| Q3 2021 | $2,115,000 | – | 93,788 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
| Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
| Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
| COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
| Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
| Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
| Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
| Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
| Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |